Cigna (CI) CEO Brian Evanko Receives Restricted Shares

What Happened Brian C. Evanko, President and Chief Executive Officer of Cigna Group (CI), was granted two equity awards on 2026-09-01: 3,113 restricted shares (acquired at $0.00) and 6,716 derivative restricted shares (also acquired at $0.00). Both entries show an acquisition price of $0.00, so no cash was paid at grant; the reported totals for each line are $0.

Key Details

• Transaction date: 2026-09-01; Form 4 filed: 2026-09-03 (appears timely).
• Grants: 3,113 restricted shares (A) and 6,716 derivative restricted shares (A), each at $0.00.
• Shares owned after transaction: Not provided in the supplied data.
• Notable footnotes from the filing:
  • F1: The restricted shares vest in three equal annual installments beginning September 1, 2027.
  • F2: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.
  • F3: Indicates an option vesting schedule (vests in three equal annual installments beginning September 1, 2027).
• Filing timeliness: Filed two days after the transaction date; no late filing flag indicated.

Context These entries are awards/grants rather than open-market purchases or sales. The restricted and derivative designations mean the shares are subject to vesting and other transfer restrictions (per F1/F3), so they do not represent immediate market purchases or sales. For retail investors, such awards are routine executive compensation and reflect long-term incentive alignment rather than a near-term bullish or bearish trade signal.